We are live on ! Find out more
TXMD icon

TherapeuticsMD

148 hedge funds and large institutions have $489M invested in TherapeuticsMD in 2019 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 59 increasing their positions, 29 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

103% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 29

26% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 19

1% more funds holding

Funds holding: 146148 (+2)

0.02% less ownership

Funds ownership: 1.59%1.57% (-0.02%)

47% less capital invested

Capital invested by funds: $932M → $489M (-$442M)

48% less call options, than puts

Call options by funds: $2.99M | Put options by funds: $5.77M

100% less funds holding in top 10

Funds holding in top 10: 20 (-2)

Holders
148
Holders Change
+2
Holders Change %
+1.37%
% of All Funds
3.2%
Holding in Top 10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
New
24
Increased
59
Reduced
29
Closed
19
Calls
$2.99M
Puts
$5.77M
Net Calls
-$2.78M
Net Calls Change
-$2.56M

TXMD Hedge Fund Activity: Q2 2019 in Review

148 of the 4,624 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q2 2019, worth a combined $489M — down 47% from $932M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new TXMD positions and 19 closed out — a net gain of 5 holders — while 59 added to existing stakes and 29 trimmed.

The largest buyer was SG Americas Securities, adding an estimated $8.29M. The largest seller was Millennium Management, cutting an estimated $11.6M.

  • 148 institutional investors held TherapeuticsMD (TXMD) as of Q2 2019, up from 146 in Q1 2019.
  • Funds reported $489M of TherapeuticsMD stock for Q2 2019, down 47% quarter-over-quarter.
  • 24 funds opened new TherapeuticsMD positions in Q2 2019 and 19 closed out, a net change of +5 holders.
  • The largest TherapeuticsMD buyer in Q2 2019 was SG Americas Securities, an estimated $8.29M added.
  • The largest TherapeuticsMD seller in Q2 2019 was Millennium Management, an estimated $11.6M sold.

Based on aggregated 13F filings for Q2 2019.